SEGMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2019

	For the Six Months Ended April 30,
	For the Six Months Ended April 30,
		2019		2018
Net loss:
Cancer Diagnostics	$	(3,052,355)	$	(1,362,451)
Cancer Therapeutics		(3,517,219)		(1,551,067)
Patent licensing		(971,969)		(344,470)
Total	$	(7,541,543)	$	(3,257,988)

Operating costs and expenses excluding non-cash share based compensation expense:
Cancer Diagnostics	$	1,417,967	$	1,075,480
Cancer Therapeutics		1,245,681		1,348,498
Patent licensing		1,091,700		1,002,879
Total	$	3,755,348	$	3,426,857

Operating costs and expenses excluding non-cash share based compensation expense	$	3,755,348	$	3,426,857
Plus non-cash share-based compensation expense		4,071,614		598,683
Total operating costs and expenses	$	7,826,962	$	4,025,540

	For the Three Months Ended April 30,
		2019		2018
Net loss:
Cancer Diagnostics	$	(1,248,001)	$	(739,202)
Cancer Therapeutics		(1,029,934)		(442,049)
Patent licensing		(296,999)		(211,263)
Total	$	(2,574,934)	$	(1,392,514)

Operating costs and expenses excluding non-cash share based compensation expense:
Cancer Diagnostics	$	658,433	$	549,866
Cancer Therapeutics		444,890		393,645
Patent licensing		418,461		875,733
Total	$	1,521,784	$	1,819,244

Operating costs and expenses excluding non-cash share based compensation expense	$	1,521,784	$	1,819,244
Plus non-cash share-based compensation expense		1,321,450		331,710
Total operating costs and expenses	$	2,843,234	$	2,150,954